Nootropic
Citicoline
SaveAn endogenous nucleotide (CDP-choline) involved in phosphatidylcholine synthesis. Studied extensively as a neuroprotectant in stroke and for age-related cognitive decline.
Quick verdict
Good safety profile and moderate evidence for cognitive support in aging populations. One of the better-evidenced cholinergic nootropics.
Evidence score
A rough internal score reflecting quantity, quality, and consistency of human evidence. Not a clinical recommendation.
What the research shows
Meta-analyses of stroke trials show mixed results for functional recovery. Trials in age-related cognitive decline and glaucoma show modest positive effects. Well-absorbed orally with good CNS penetration.
Benefits
- Supports phospholipid membrane synthesis
- Modest improvements in memory and attention in older adults
- Well tolerated with a strong safety record
Dosage notes
250–1000 mg/day orally. The 500 mg dose is most commonly used in cognitive trials.
Side effects
- Headache (uncommon)
- Insomnia
- GI discomfort
Who should be cautious
Generally well tolerated. Rare cases of insomnia, headache, or digestive upset. Interactions with levodopa are possible.
What this page cannot tell you
Stroke-recovery evidence is inconsistent. Cognitive benefits in healthy young adults are less established.
Leaderboard scores
- Memory55
- Focus50
- Longevity35
Featured in protocols
Write a review
Sign in to write a review.